Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTICOV immunology ancillary study in mild to moderate COVID-19
PACTR202010781639956Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Paracetamol control arm, Hydroxychloroquine arm and Lopinavir + ritonavir arm (3 arms). Started Sep 2020; status: completed.
02
Drugs
acetaminophenhydroxychloroquinelopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202010781639956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202010781639956.